

Resource Summary Report

Generated by [NIF](#) on Aug 11, 2026

Yoda Project

RRID:SCR_022761

Type: Tool

Proper Citation

Yoda Project (RRID:SCR_022761)

Resource Information

URL: <https://yoda.yale.edu/>

Proper Citation: Yoda Project (RRID:SCR_022761)

Description: Project to promote and facilitate sharing of clinical trial data. Provides set of policies to set standards to enhance data availability and transparency in support of strong scientific research which aims to advance scientific and medical knowledge with goal of improving public health and healthcare delivery. Project has the final decision making rights regarding these policies and granting or denial of data requests, as per contractual agreements between the YODA Project and its partners.

Synonyms: Yale university Open Data Access project, YODA Project, Yale University Open Data Access Project

Resource Type: data or information resource, project portal, portal

Keywords: Data sharing project for clinical trials, clinical trial data, policies, standards to enhance data availability and transparency, granting or denial of data requests

Availability: Free, Freely available

Resource Name: Yoda Project

Resource ID: SCR_022761

Record Creation Time: 20220920T050146+0000

Record Last Update: 20260811T043712+0000

Ratings and Alerts

No rating or validation information has been found for Yoda Project.

No alerts have been found for Yoda Project.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 299 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

O'Hagan A, et al. (2026) Incidence and outcomes of FGFR inhibitor-associated retinopathy of patients treated with oral erdafitinib across the clinical trial program. The oncologist, 31(7).

Bertamini L, et al. (2026) Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone. Blood, 147(4), 431.

Arjuman A, et al. (2026) In conversation with Dr. Joseph S. Ross: Utility and issues around clinical datasets, the example of the YODA project. The Indian journal of medical research, 163(2), 134.

Lam E, et al. (2026) Pharmacokinetics and Safety of Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Results of the Real-World Ustekinumab Pediatric Opportunistic Pharmacokinetics Study (U-POPS). Rheumatology and therapy, 13(1), 265.

Xu J, et al. (2026) Association between COVID-19 vaccine efficacy and epidemic force of infection. NPJ vaccines, 11(1), 54.

Cardé NAQ, et al. (2026) Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine Dynamics. Targeted oncology, 21(3), 373.

De Greef E, et al. (2026) Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg. Journal of Crohn's & colitis, 20(3).

Pinter C, et al. (2026) Safety, tolerability, and preliminary efficacy of seltorexant versus quetiapine extended release as adjunctive therapy in major depressive disorder: a randomized, flexible-dose, 6-month, parallel-group, exploratory study. The international journal of neuropsychopharmacology, 29(4).

Sommer P, et al. (2026) Workflow and sedation choice with the PFA variable-loop circular catheter in real-world AF procedures: insights from the prospective multi-centre VARIPURE clinical study. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 28(2).

Csonka D, et al. (2026) Effect of Once-Daily Macitentan 75 mg on the Pharmacokinetics of Sildenafil, Riociguat, or Rosuvastatin in Healthy Male Participants. Journal of clinical pharmacology, 66(4), e70185.

Yu F, et al. (2026) Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials. *Human vaccines & immunotherapeutics*, 22(1), 2664331.

Lopez-Muñoz N, et al. (2026) Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison. *Advances in therapy*, 43(3), 1327.

Ruopp NF, et al. (2026) Predictive Value of the Pulmonary Artery Pulsatility Index in Pulmonary Arterial Hypertension: REVEAL Analysis. *Cardiology research*, 17(3), 214.

Seridi L, et al. (2026) Reproducible Molecular Subtypes in Systemic Lupus Erythematosus Are Associated With Disease Activity, Serology, and Distinct Trajectories Over Time. *ACR open rheumatology*, 8(7), e90083.

Gossec L, et al. (2026) Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study. *Rheumatology and therapy*, 13(2), 347.

Loriot Y, et al. (2026) Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 44(8), 676.

Gladman DD, et al. (2026) Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials. *Rheumatology and therapy*, 13(1), 213.

Ito S, et al. (2026) Talquetamab in Japanese patients with relapsed/refractory multiple myeloma in the MonumenTAL-1 study. *International journal of hematology*, 123(4), 580.

Marzo-Ortega H, et al. (2026) Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS post hoc analysis. *Rheumatology (Oxford, England)*, 65(1).

Mina R, et al. (2026) Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial. *Journal of patient-reported outcomes*, 10(1).